STOCK TITAN
  1. Home
  2. News
  3. RCKT

Rocket Pharmaceuticals Inc - RCKT STOCK NEWS

Welcome to our dedicated news page for Rocket Pharmaceuticals (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rocket Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rocket Pharmaceuticals's position in the market.

News
Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. announces pricing of public offering, expected to raise approximately $175 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.85%
Tags
offering
-
News
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. plans to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering, expecting gross proceeds of $150 million. The offering is subject to market conditions and the company has granted the underwriters a 30-day option to purchase up to an additional 15 percent of shares. J.P. Morgan, Morgan Stanley, Leerink Partners, and TD Cowen are acting as joint book-running managers. The offering is being made pursuant to an effective shelf registration statement previously filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.85%
Tags
offering
-
News
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
Rhea-AI Summary
Rocket Pharmaceuticals reaches alignment with FDA on pivotal trial for RP-A501 in Danon Disease, a genetic therapy for heart disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.85%
Tags
clinical trial
News
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Rocket Pharmaceuticals to participate in Morgan Stanley and Cantor Fitzgerald healthcare conferences in September 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
conferences
-
News
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
Rhea-AI Summary
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported financial results for the quarter ending June 30, 2023, and updates on key pipeline developments. The company is advancing an integrated pipeline of genetic therapies for rare disorders. The PR highlights the progress in various gene therapy programs, including RP-A501 (Danon Disease), RP-L201 (LAD-I), RP-A601 (PKP2-ACM), RP-L102 (Fanconi Anemia), and RP-L301 (PKD). The company also provided an operational update and financial results, including cash position and net loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
earnings
-
News
Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
Rhea-AI Summary
Rocket Pharmaceuticals has received Fast Track and Orphan Drug designations from the FDA for its gene therapy candidate, RP-A601, for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). The company plans to initiate a Phase 1 trial to evaluate the safety and efficacy of RP-A601 in adult PKP2-ACM patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
clinical trial
News
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none
-
News
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
Rhea-AI Summary
Rocket Pharmaceuticals receives RMAT designation from FDA for gene therapy treatment for Pyruvate Kinase Deficiency
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
News
Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
News
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
clinical trial
Stock RCKT logo
Rocket Pharmaceuticals Inc

Nasdaq:RCKT

RCKT Rankings

#1837 Ranked by Market Cap
#2303 Ranked by Stock Gains
N/A Ranked by Dividends

RCKT Stock Data

2.19B
70.94M
3.66%
102.05%
11.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About RCKT

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.